NCT01123356已完成2 期
Phase 2 Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 2
- 主要终点
- Overall Response Rate
研究概览
简要总结
The purpose of this research is to evaluate the safety and effectiveness of the drugs lenalidomide and ofatumumab in the treatment of chronic lymphocytic leukemia (CLL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must have confirmed diagnosis of chronic lymphocytic leukemia (CLL).
- •Prior therapy with at least one regimen containing rituximab
- •Age > 18 years.
- •Life expectancy greater than 12 months.
- •ECOG performance status <2
- •Patients must have normal organ function as defined in the protocol.
- •Patients must have adequate bone marrow function as defined in the protocol.
- •Ability to understand and the willingness to sign a written informed consent document.
- •All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.
- •Females of childbearing potential (FCBP)† must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours prior to prescribing lenalidomide (prescriptions must be filled within 7 days) and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy.
- •Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin.
排除标准
- •Patients who have had chemotherapy or radiotherapy within 4 weeks or received any monoclonal antibody within 6 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
- •Patients may not be receiving any other investigational agents or other anti-cancer agents or treatments.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to ofatumumab or lenalidomide.
- •Uncontrolled concomitant illness.
- •Pregnant women are excluded from this study because lenalidomide is believed to be teratogenic.
- •HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ofatumumab or lenalidomide.
- •Prior treatment with lenalidomide
- •Evidence of laboratory TLS by Cairo-Bishop Definition of Tumor Lysis Syndrome. Subjects may be enrolled upon correction of electrolyte abnormalities.
- •All patients will undergo screening for hepatitis B and may or may not be eligible based on the results as outlined in the protocol.
研究组 & 干预措施
Oratumumab and Lenalidomide
Experimental
Single arm, non randomized study
Ofatumumab, Lenalidomide: -Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1.
- Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28.
- Treatment to be administered for up to 6 cycles
干预措施: Ofatumumab (Drug)
Oratumumab and Lenalidomide
Experimental
Single arm, non randomized study
Ofatumumab, Lenalidomide: -Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1.
- Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28.
- Treatment to be administered for up to 6 cycles
干预措施: Lenalidomide (Drug)
结局指标
主要结局
Overall Response Rate
时间窗: 30 Weeks
Obtain early assessment of the efficacy of the intracycle sequential administration of ofatumumab and lenalidomide in the treatment of chronic lymphocytic leukemia (CLL) after prior use of rituximab. Response was categorized according to the IW-CLL criteria which includes the following: Complete remission (CR), CR with incomplete marrow recovery (CRi)Partial remission (PR), Progressive disease (PD), Stable disease (SD). Overall response rate was defined as those who experienced a response of CR, CRi or PR.
次要结局
- Frequency of Adverse and Severe Adverse Events(30 weeks)
- Biomarkers Changes During Treatment.(30 Weeks)
- Frequency of Adverse Events(30 weeks)
- Dose Reductions Due to Adverse Events.(30 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT01060384University of Nebraska46
已完成
2 期
Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell LymphomaDiffuse Large B-cell LymphomaNCT00799513IRCCS San Raffaele48
终止
1 期
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPDiffuse Large B-cell Lymphoma (DLBCL)Follicular Lymphoma Grade III (FL III°)Mantle Cell Lymphoma (MCL), Blastoid VariantBurkitt Lymphoma (BL)Aggressive Marginal Zone Lymphoma (MZL)NCT02983097Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH34
已完成
2 期
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaFatigueFeverHypogammaglobulinemiaLymphadenopathyLymphocytosisNight SweatsParaproteinemiaSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaThrombocytopeniaNCT01002755M.D. Anderson Cancer Center36
已完成
2 期
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT02135133Dana-Farber Cancer Institute27